Orexigen Therapeutics (OREX) Tops Q1 EPS by 2c, Sales Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
May 4, 2016 4:01 PM EDTSAN DIEGO, May 4, 2016 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.
"In preparation for the completion of our acquisition of U.S. rights to Contrave® (naltrexone HCl/bupropion HCl extended release), our team has made rapid progress advancing our commercial plans, including assembling talented and experienced sales and marketing leadership," said Mike Narachi, CEO of Orexigen.
Narachi continued: "We believe patients seeking medication-assisted weight loss deserve new alternatives to the treatment most commonly offered today, generic amphetamines... More
